Sermorelin vs. Tesamorelin: How They Differ, What the Evidence Shows, and What to Monitor

The shared mechanism

Your hypothalamus makes growth-hormone-releasing hormone (GHRH), which tells the pituitary gland to release growth hormone in pulses. Sermorelin and tesamorelin are both lab-made versions of GHRH. Instead of injecting growth hormone itself, they nudge your own system to make more. That's why clinicians often describe them as working "with" the body's feedback loops rather than overriding them.

Growth hormone's effects mostly travel through IGF-1, a hormone made in the liver. That's why IGF-1 is the main number clinicians watch on either peptide.

Sermorelin: the compounded classic

Sermorelin is the first 29 amino acids of natural GHRH, the part that does the signaling. It was approved by the FDA in 1997 under the brand name Geref, mainly for children with growth hormone deficiency and as a diagnostic test. The manufacturer stopped making it in 2008 for commercial reasons, and the FDA later determined it wasn't withdrawn for safety or effectiveness.

Because it once had an approved application, sermorelin can be prepared by licensed compounding pharmacies with a prescription. It's commonly prescribed off-label for adults interested in sleep, recovery and body composition. The human evidence for those adult uses is thinner than many marketing claims suggest, so expectations should be modest and tracked with labs.

Tesamorelin: approved, but for a narrow use

Tesamorelin is a modified GHRH that lasts longer in the body. It's FDA-approved as Egrifta, currently sold as Egrifta WR and Egrifta SV, for reducing excess abdominal fat in adults with HIV who have lipodystrophy. The label is specific about what it is not: it isn't indicated for weight loss, and long-term cardiovascular safety hasn't been established.

Clinicians sometimes prescribe it off-label for stubborn visceral fat. If you're considering it, it helps to know the label's warnings, which apply whatever the reason for using it.

Side by side

Safety: what the tesamorelin label tells us

The Egrifta label lists several warnings that are a useful guide to the whole category:

• Blood sugar. It can cause glucose intolerance or new diabetes, so glucose should be checked before starting and periodically after.
• IGF-1. It raises IGF-1, and the effects of long-term elevation aren't known. The label suggests considering stopping if IGF-1 stays well above normal.
• Fluid retention. Swelling, joint pain and carpal tunnel symptoms can occur, usually temporary.
• Cancer. It shouldn't be used with active cancer.
• Pregnancy. It's contraindicated.

Sermorelin works through the same pathway, so clinicians generally apply the same caution around blood sugar, IGF-1 and cancer history.

The labs that matter

For either peptide, expect a baseline IGF-1, fasting glucose or A1c, and a metabolic panel before starting. IGF-1 is usually rechecked within the first few months to guide the dose, then periodically. Our bloodwork guide lays out the full before-and-during list.

Which one makes sense?

That's a clinician's call, and it depends on your goal, history and budget. In general, tesamorelin has stronger trial data for one specific outcome, visceral fat, and comes as an approved product. Sermorelin is more often used for broader healthy-aging goals and is typically less expensive. Neither is a shortcut, and both work best alongside sleep, training and nutrition.